|
Ben Steele talks with Eduardo Tchouhadjian, CEO of E. Tchouhadjian & Associates, about how companies in Latin America are responding to the rise of the ‘smart patient’ and how to use “360-degree marketing” to combat the issue of prescription switching in these fast-growing markets.
Highlighting the main trends seen in the activities of the European Medicines Agency, its 2012 annual report summarises some key topics of current interest including gene-therapy and drug regulation.
Merck & Co has announced it will be investing nearly $120 million in a new pharmaceutical manufacturing facility in Hangzhou, China.
This week U.S democrats have introduced legislation into Congress that would require drug companies to provide rebates on prescription drugs used by people on both Medicare prescription drug (Part D) and Medicaid programmes, in the hope of saving the taxpayer over $140 billion.
India’s Supreme Court rejected Novartis’ patent application for the cancer drug Glivec yesterday. A victory for the Indian drug industry, but the result may have repercussions on India’s attempts to attract foreign investment
Budget cuts slashing American spending on healthcare and research by US$85bn (£56bn) as part of a ten-year schedule aimed to save US$1.2 trillion, will begin next week, making public health sector take a hit surpassed only by trimmings made in defense.
Johnson and Johnson recalls their OneTouch Verio line of blood glucose meters, after the death of a patient.
GW Pharma and partner Almirall have said they may have to suspend sales or pull Sativex from the German market as price negotiations with the country’s authorities reaches a standstill.
The World Trade Organization has postponed a decision on whether they will extend the July 2013 deadline for the implementation of the TRIPS agreement in developing countries, putting into doubt whether life-saving medicines will continue to be widely available to the poorest nations.
Ben Steele talks with Eduardo Tchouhadjian, CEO of E. Tchouhadjian & Associates, about how...
Lucy Brake speaks to Mike Rea, CEO of IDEA Pharma, about how he believes real world evidence...
India’s Drug Controller General is to increase monitoring of clinical trials following health...
